Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients With Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Treatment With Immunosuppressants
Sponsor: Alexion Pharmaceuticals, Inc.
This PHASE2 trial investigates Myasthenia Gravis and is currently terminated or withdrawn. Alexion Pharmaceuticals, Inc. leads this study, which shows 14 recorded versions since 2008 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Apr 2023 — Dec 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Apr 2023 [monthly]
Terminated PHASE2
▶ Show 9 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Oct 2019 — Nov 2020 [monthly]
Terminated PHASE2
-
Jun 2019 — Oct 2019 [monthly]
Terminated PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alexion Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .